India, Nov. 6 -- Shares of Xencor Inc. (XNCR), a clinical-stage biopharmaceutical company pioneering engineered antibodies for cancer and autoimmune diseases, have had a remarkable run so far this year as its clinical pipeline gathers pace and the promise of scientific advances draws investor attention.
The company's clinical drug candidates are based on its proprietary XmAb protein engineering platform.
XmAb protein engineering platform fine-tunes antibodies by making small, precise changes to their Fc domain - the stem of the structure that is responsible for antibodies' natural immune functions and highly stable structure. These carefully designed changes can significantly enhance an antibody's performance. What makes the platform part...